Article
Oncology
Xiaoxiao Jin, Xiaotao Liu, Zining Zhou, Yan Ding, Yandan Wu, Jie Qiu, Chuanlai Shen
Summary: In this study, 25 HLA-A0201 restricted GPC3 epitopes were predicted and 5 were identified as real-world epitopes for specific CD8(+) T cell activation. These epitopes were further confirmed to induce robust CD8(+) T cell responses and cytotoxicity targeting HepG2 cells, providing potential for the development of T cell epitope vaccines and evaluation of GPC3 specific T cell responses.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Immunology
Mehdi Khelfa, Mathieu Leclerc, Stephane Kerbrat, Yakout Nait Sidenas Boudjemai, Medine Benchouaia, Deborah Neyrinck-Leglantier, Leonie Cagnet, Lylia Berradhia, Marie Tamagne, Laure Croisille, France Pirenne, Sebastien Maury, Benoit Vingert
Summary: Acute myeloid leukemia (AML) requires multiple platelet transfusions, which can trigger an immune response against platelets. This study analyzed the immune activation profiles of AML patients with or without anti-HLA alloimmunization and found differences in the phenotype and function of CD4+ T lymphocytes. These findings have implications for understanding immune responses in AML patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Surgery
Johanna C. Wagner, Emilie Ronin, Patrick Ho, Yani Peng, Qizhi Tang
Summary: CAR Treg therapy targeting donor alloantigens has shown efficacy in prolonging graft survival in vascularized transplant models, offering a potential solution for reducing immunosuppression.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Article
Immunology
Yannick D. Muller, Leonardo M. R. Ferreira, Emilie Ronin, Patrick Ho, Vinh Nguyen, Gaetano Faleo, Yu Zhou, Karim Lee, Kevin L. Leung, Nikolaos Skartsis, Anupurna M. Kaul, Arend Mulder, Frans H. J. Claas, James A. Wells, Jeffrey A. Bluestone, Qizhi Tang
Summary: The study demonstrates that genome-engineered mono-antigen-specific A2-CAR Tregs can localize to HLA-A2-expressing grafts and exhibit antigen-dependent in vivo suppression. These Tregs do not impair the function of islets and can delay graft-versus-host disease. This approach may be applied towards developing precision Treg cell therapies for transplant tolerance.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Eugene Shenderov, Matheswaran Kandasamy, Uzi Gileadi, Jili Chen, Dawn Shepherd, James Gibbs, Gennaro Prota, Jonathan D. Silk, Jonathan W. Yewdell, Vincenzo Cerundolo
Summary: The NY-ESO-1 T cell receptor (TCR) transgenic mouse model provides a unique opportunity for studying TCR response avidity against this tumor-specific antigen, with the potential to accelerate clinical development of tumor vaccines and cell therapies targeted at NY-ESO-1.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Chemistry, Multidisciplinary
Yi-chen Lei, Xin-jie Chen, Yu-ting Dai, Bing Dai, Ji-yue Wang, Miao-hui Li, Ping Liu, Han Liu, Kan-kan Wang, Lu Jiang, Bing Chen
Summary: This study investigated the combination therapy of agents targeting RUNX1-RUNX1T1 and KIT in the treatment of AML with t(8;21) and KIT mutations. The results showed that the combination of eriocalyxin B (EriB) and homoharringtonine (HHT) exerted synergistic therapeutic effects by dual inhibition of RUNX1-RUNX1T1 and KIT proteins in cells and mouse models.
ACTA PHARMACOLOGICA SINICA
(2023)
Article
Oncology
Xin Liu, Yixiang Xu, Wei Xiong, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Yang Du, Tianhao Duan, Helen Y. Wang, Ningyan Zhang, John S. Yu, Zhiqiang An, Rongfu Wang
Summary: This study developed a TCR-like antibody and CAR-T cells to recognize intracellular proteins as a target for cancer immunotherapy. The specificity and antitumor activity of the antibody and CAR-T cells were demonstrated both in vitro and in vivo, providing a novel approach for the development of cancer immunotherapeutics.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Liping Zhong, Wei Shi, Lu Gan, Xiuli Liu, Yu Huo, Pan Wu, Zhikun Zhang, Tao Wu, Hongmei Peng, Yong Huang, Yongxiang Zhao, Yulin Yuan, Zhiming Deng, Hongliang Tang
Summary: A bispecific T-cell engager antibody targeting human endoglin and CD3 was constructed in this study, showing therapeutic potential in cancer treatment. In vivo experiments demonstrated that the antibody significantly reduced tumor growth and neoangiogenesis, leading to improved mouse survival.
Article
Immunology
Alexander Hellesen, Sigrid Aslaksen, Lars Breivik, Ellen Christine Royrvik, Oyvind Bruserud, Kine Edvardsen, Karl Albert Brokstad, Anette Susanne, Boe Wolff, Eystein Sverre Husebye, Eirik Bratland
Summary: In patients with AAD, a significantly higher frequency of HLA-A2 restricted LLNATIAEV-specific cells was found compared to controls. However, negligible frequencies of EPLARLEL-specific T cells were detected, with significant IFNγ production observed in response to a longer peptide encompassing EPLARLEL. The slightly offset ARLELFVVL peptide was identified as a novel dominant epitope restricted by HLA-C7.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Manley T. F. Huang, Vikram Sharma, Andrew Mendelsohn, Qisheng Wei, Jinjing Li, Bo Yu, James W. Larrick, Lawrence G. Lum
Summary: Bispecific antibody (BiAb)-armed activated T cells (BATs) show promise as a novel adoptive T cell therapy platform for treating various types of cancer.
ANNALS OF MEDICINE
(2022)
Article
Engineering, Biomedical
Kuo Zhang, Hui Zhang, Xiao-Ran Zou, Ying Hu, Da-Yong Hou, Jia-Qi Fan, Chao Yang, Zi-Ming Chen, Shi-Fang Wen, Hui Cao, Pei-Pei Yang, Lei Wang
Summary: ALPN is a biomimetic superstructure drug targeting NRP-1 to inhibit angiogenesis in the treatment of CNV. It shows high efficacy in CNV rat model and has potential advantages over traditional monoclonal antibodies with similar anti-angiogenesis effect at low doses.
Article
Oncology
Upasana Sunil Arvindam, Paulien M. M. van Hauten, Dawn Schirm, Nicolaas Schaap, Willemijn Hobo, Bruce R. Blazar, Daniel A. Vallera, Harry Dolstra, Martin Felices, Jeffrey S. Miller
Summary: The development of a CLEC12A TriKE molecule targeting AML blasts and LSCs, which activates NK cells and drives NK cell priming while sparing healthy cells, highlights the potential clinical efficacy for the treatment of AML.
Article
Immunology
Josien Lanfermeijer, Marieke M. Nuehn, Maarten E. Emmelot, Martien C. M. Poelen, Cecile A. C. M. van Els, Jose A. M. Borghans, Debbie van Baarle, Patricia Kaaijk, Jelle de Wit
Summary: Decrease in MuV-specific humoral response after vaccination may contribute to recent mumps outbreaks, but CD8(+) T cells could play a key role in the immune response against MuV. The frequency of MuV-specific CD8(+) T cells in the blood declines within 9 months post-infection, although the TCR beta analysis reveals a stable MuV-specific T-cell repertoire over time.
Article
Immunology
Zhiwei Wang, Ling Ran, Chunxia Chen, Ranran Shi, Yu Dong, Yubing Li, Xiuman Zhou, Yuanming Qi, Pingping Zhu, Yanfeng Gao, Yahong Wu
Summary: In this study, 35 HLA-A2-restricted mutant peptides from ESCC were selected, with seven of them showing strong binding affinity to HLA-A*0201 molecules and forming stable complexes. Three of these mutant peptides were immunogenic and able to induce CTL recognition in an HLA-A2-restricted and MUT peptide-specific manner. Enhancing CTL response in immunized mice was achieved by coupling MUT peptides with a peptide delivery carrier targeting DCs.
Article
Immunology
Cara E. Ellis, Majid Mojibian, Shogo Ida, Vivian C. W. Fung, Sos Skovso, Emma McIver, Shannon O'Dwyer, Travis D. Webber, Mitchell J. S. Braam, Nelly Saber, Shugo Sasaki, Francis C. Lynn, Timothy J. Kieffer, Megan K. Levings
Summary: This study used A2-CAR T cells to investigate the rejection of insulin-producing cells and successfully addressed the issue of complications from xenogeneic graft-versus-host disease.
Article
Biophysics
Piyanuch Kongtim, Simrit Parmar, Denai R. Milton, Jorge Miguel Ramos Perez, Gabriela Rondon, Julianne Chen, Abhishek R. Chilkulwar, Gheath Al-Atrash, Amin Alousi, Borje S. Andersson, Jin S. Im, Chitra M. Hosing, Qaiser Bashir, Issa Khouri, Partow Kebriaei, Betul Oran, Uday Popat, Richard Champlin, Stefan O. Ciurea
BONE MARROW TRANSPLANTATION
(2019)
Article
Biophysics
Gheath Alatrash, Kelly M. Kidwell, Peter F. Thall, Antonio Di Stasi, Julianne Chen, Madhushree Zope, Alyssa K. Crain, Richard E. Champlin, Uday Popat, Elizabeth J. Shpall, Roy B. Jones, Borje S. Andersson
BONE MARROW TRANSPLANTATION
(2019)
Article
Oncology
Patrick Williams, Sreyashi Basu, Guillermo Garcia-Manero, Christopher S. Hourigan, Karolyn A. Oetjen, Jorge E. Cortes, Farhad Ravandi, Elias J. Jabbour, Zainab Al-Hamal, Marina Konopleva, Jing Ning, Lianchun Xiao, Juliana Hidalgo Lopez, Steve M. Kornblau, Michael Andreeff, Wilmer Flores, Carlos Bueso-Ramos, Jorge Blando, Pallavi Galera, Katherine R. Calvo, Gheath Al-Atrash, James P. Allison, Hagop M. Kantarjian, Padmanee Sharma, Naval G. Daver
Article
Oncology
Gheath Alatrash, Na Qiao, Mao Zhang, Madhushree Zope, Alexander A. Perakis, Pariya Sukhumalchandra, Anne Philips, Haven R. Garber, Celine Kerros, Lisa S. St John, Maria R. Khouri, Hiep Khong, Karen Clise-Dwyer, Leonard P. Miller, Steve Wolpe, Willem W. Overwijk, Jeffrey J. Molldrem, Qing Ma, Elizabeth J. Shpall, Elizabeth A. Mittendorf
CLINICAL CANCER RESEARCH
(2019)
Article
Immunology
Amanda C. Herrmann, Jin S. Im, Sumedha Pareek, Wilfredo Ruiz-Vasquez, Sijie Lu, Anna Sergeeva, Jennifer Mehrens, Hong He, Gheath Alatrash, Pariya Sukhumalchandra, Lisa St. John, Karen Clise-Dwyer, Dongxing Zha, Jeffrey J. Molldrem
FRONTIERS IN IMMUNOLOGY
(2019)
Article
Hematology
Kamal Chamoun, Denai R. Milton, Celina Ledesma, Ken H. Young, Elias J. Jabbour, Gheath Alatrash, Paolo Anderlini, Qaiser Bashir, Stefan O. Ciurea, David Marin, Jeffrey J. Molldrem, Amanda L. Olson, Betul Oran, Uday R. Popat, Gabriela Rondon, Richard E. Champlin, Alison M. Gulbis, Issa F. Khouri
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2019)
Letter
Hematology
Rohtesh S. Mehta, Roland Bassett, Amanda Olson, Julianne Chen, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Gheath Al-Atrash, Qaiser Bashir, Stefan O. Ciurea, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Jeffrey J. Molldrem, Yago Nieto, Betul Oran, Katayoun Rezvani, Muzaffar H. Qazilbash, Samer A. Srour, Elizabeth J. Shpall, Borje S. Andersson, Richard E. Champlin, Uday R. Popat
Article
Oncology
Peter S. N. van Rossum, Wei Deng, David M. Routman, Amy Y. Liu, Cai Xu, Yutaka Shiraishi, Max Peters, Kenneth W. Merrell, Christopher L. Hallemeier, Radhe Mohan, Steven H. Lin
PRACTICAL RADIATION ONCOLOGY
(2020)
Article
Hematology
Samer A. Srour, Rima M. Saliba, Maria C. B. Bittencourt, Jorge M. R. Perez, Piyanuch Kongtim, Amin Alousi, Gheath Al-Atrash, Amanda Olson, Oran Betul, Rohtesh Mehta, Uday Popat, Chitra Hosing, Qaiser Bashir, Issa Khouri, Partow Kebriaei, Lucia Masarova, Nicholas Short, Elias Jabbour, Naval Daver, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian, Richard E. Champlin, Stefan O. Ciurea
AMERICAN JOURNAL OF HEMATOLOGY
(2019)
Article
Oncology
G. Travis Clifton, Diane Hale, Timothy J. Vreeland, Annelies T. Hickerson, Jennifer K. Litton, Gheath Alatrash, Rashmi K. Murthy, Na Qiao, Anne V. Philips, Jason J. Lukas, Jarrod P. Holmes, George E. Peoples, Elizabeth A. Mittendorf
CLINICAL CANCER RESEARCH
(2020)
Article
Oncology
Hong He, Yukio Kondo, Ken Ishiyama, Gheath Alatrash, Sijie Lu, Kathryn Cox, Na Qiao, Karen Clise-Dwyer, Lisa St John, Pariya Sukhumalchandra, Qing Ma, Jeffrey J. Molldrem
Article
Oncology
Cai Xu, Jian-Yue Jin, Ming Zhang, Amy Liu, Jun Wang, Radhe Mohan, Fengming (Spring) Kong, Steven H. Lin
RADIOTHERAPY AND ONCOLOGY
(2020)
Article
Oncology
Sung-Eun Lee, Feng Wang, Maison Grefe, Abel Trujillo-Ocampo, Wilfredo Ruiz-Vasquez, Koichi Takahashi, Hussein A. Abbas, Pamella Borges, Dinler Amaral Antunes, Gheath Al-Atrash, Naval Daver, Jeffrey J. Molldrem, Andrew Futreal, Guillermo Garcia-Manero, Jin S. Im
Summary: The purpose of this study is to find immune-related biomarkers to predict effective antitumor immunity in myelodysplastic syndrome (MDS) during immunotherapy and/or hypomethylating agent treatment. Peripheral blood samples from 55 MDS patients were analyzed for immune subsets, T-cell receptor repertoire, gene mutations, and immune-related gene expression profiling. The results showed that clinical responders to immunotherapy exhibited expansion of central memory CD8+ T cells, diverse TCR repertoire, higher mutation burden, and favorable changes in immune landscape.
CLINICAL CANCER RESEARCH
(2023)
Article
Hematology
Uday R. Popat, Oren Pasvolsky, Roland Bassett Jr, Rohtesh S. Mehta, Amanda Olson, Julianne Chen, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Terri Lynn Shigle, Samer A. Srour, Jeremy L. Ramdial, Katayoun Rezvani, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall
Summary: A fractionated myeloablative busulfan regimen was found to be effective in reducing nonrelapse mortality without increasing relapse rate for patients undergoing allogeneic hematopoietic cell transplantation, especially for older patients and those with comorbidities.
Article
Engineering, Biomedical
Cong Zhu, Steven H. Lin, Xiaoqian Jiang, Yang Xiang, Zayne Belal, Goo Jun, Radhe Mohan
PHYSICS IN MEDICINE AND BIOLOGY
(2020)